메뉴 건너뛰기




Volumn 3, Issue 1, 2015, Pages

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade

Author keywords

CD8+ T cells; CTLA 4; Immunotherapy; Interleukin 2; NK cells

Indexed keywords

9H10 MONOCLONAL ANTIBODY; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CREATININE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOSE; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 2 ANTIBODY; IPILIMUMAB; MONOCLONAL ANTIBODY; PHOSPHORUS; PROTEIN; UNCLASSIFIED DRUG;

EID: 84998981036     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0063-3     Document Type: Article
Times cited : (51)

References (50)
  • 1
    • 84907624135 scopus 로고    scopus 로고
    • Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence
    • Mrazek AA, Chao C. Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence. Surg Clin North Am. 2014;94(5):989-1002. vii-viii. doi:10.1016/j.suc.2014.07.003.
    • (2014) Surg Clin North Am , vol.94 , Issue.5 , pp. 989-1002
    • Mrazek, A.A.1    Chao, C.2
  • 2
    • 84919682995 scopus 로고    scopus 로고
    • Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects
    • Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. Clini Cancer Res. 2014. doi:10.1158/1078-0432.CCR-14-1457.
    • (2014) Clini Cancer Res
    • Antonia, S.J.1    Larkin, J.2    Ascierto, P.A.3
  • 3
    • 84895794537 scopus 로고    scopus 로고
    • Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors
    • Das Thakur M, Stuart DD. Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors. Clin Cancer Res. 2014;20(5):1074-80. doi:10.1158/1078-0432.CCR-13-0103.
    • (2014) Clin Cancer Res , vol.20 , Issue.5 , pp. 1074-1080
    • Das Thakur, M.1    Stuart, D.D.2
  • 4
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. doi:10.1056/NEJMoa1103782.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3    Haanen, J.B.4    Ascierto, P.5    Larkin, J.6
  • 6
    • 84897531613 scopus 로고    scopus 로고
    • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
    • Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508(7494):118-22. doi:10.1038/nature13121.
    • (2014) Nature , vol.508 , Issue.7494 , pp. 118-122
    • Sun, C.1    Wang, L.2    Huang, S.3    Heynen, G.J.4    Prahallad, A.5    Robert, C.6
  • 7
    • 84902191817 scopus 로고    scopus 로고
    • IL-2: the first effective immunotherapy for human cancer
    • Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451-8. doi:10.4049/jimmunol.1490019.
    • (2014) J Immunol , vol.192 , Issue.12 , pp. 5451-5458
    • Rosenberg, S.A.1
  • 8
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64. doi:10.1038/nrc3239.
    • (2012) Nat Rev Cancer , vol.12 , Issue.4 , pp. 252-264
    • Pardoll, D.M.1
  • 9
    • 84894107349 scopus 로고    scopus 로고
    • New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape
    • Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-25. doi:10.1016/j.coi.2014.01.004.
    • (2014) Curr Opin Immunol , vol.27 , pp. 16-25
    • Mittal, D.1    Gubin, M.M.2    Schreiber, R.D.3    Smyth, M.J.4
  • 10
    • 84977118146 scopus 로고    scopus 로고
    • Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
    • Payne R, Glenn L, Hoen H, Richards B, Smith 2nd JW, Lufkin R, et al. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer. 2014;2:13. doi:10.1186/2051-1426-2-13.
    • (2014) J Immunother Cancer , vol.2 , pp. 13
    • Payne, R.1    Glenn, L.2    Hoen, H.3    Richards, B.4    Smith, J.W.5    Lufkin, R.6
  • 11
    • 84923266973 scopus 로고    scopus 로고
    • Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
    • Lebbe C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol. 2014;25(11):2277-84. doi:10.1093/annonc/mdu441.
    • (2014) Ann Oncol , vol.25 , Issue.11 , pp. 2277-2284
    • Lebbe, C.1    Weber, J.S.2    Maio, M.3    Neyns, B.4    Harmankaya, K.5    Hamid, O.6
  • 13
    • 84907979458 scopus 로고    scopus 로고
    • The IL-2 cytokine family in cancer immunotherapy
    • Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):377-90. doi:10.1016/j.cytogfr.2014.07.018.
    • (2014) Cytokine Growth Factor Rev , vol.25 , Issue.4 , pp. 377-390
    • Sim, G.C.1    Radvanyi, L.2
  • 14
    • 0033848628 scopus 로고    scopus 로고
    • High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update
    • Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6 Suppl 1:S11-4.
    • (2000) Cancer J Sci Am , vol.6 , pp. S11-S14
    • Atkins, M.B.1    Kunkel, L.2    Sznol, M.3    Rosenberg, S.A.4
  • 15
    • 0020658493 scopus 로고
    • Interleukin 2: biology and biochemistry
    • Gillis S. Interleukin 2: biology and biochemistry. J Clin Immunol. 1983;3(1):1-13.
    • (1983) J Clin Immunol , vol.3 , Issue.1 , pp. 1-13
    • Gillis, S.1
  • 16
    • 38849108168 scopus 로고    scopus 로고
    • Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling
    • Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol. 2007;179(11):7295-304.
    • (2007) J Immunol , vol.179 , Issue.11 , pp. 7295-7304
    • Elpek, K.G.1    Yolcu, E.S.2    Franke, D.D.3    Lacelle, C.4    Schabowsky, R.H.5    Shirwan, H.6
  • 17
    • 0029161529 scopus 로고
    • Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells
    • Wang MG, Szebeni J, Pearson DA, Szot GL, Sykes M. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells. Transplantation. 1995;60(5):481-90.
    • (1995) Transplantation , vol.60 , Issue.5 , pp. 481-490
    • Wang, M.G.1    Szebeni, J.2    Pearson, D.A.3    Szot, G.L.4    Sykes, M.5
  • 18
    • 84886258411 scopus 로고    scopus 로고
    • IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes
    • Diaz-de-Durana Y, Lau J, Knee D, Filippi C, Londei M, McNamara P, et al. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. PLoS One. 2013;8(10), e78483. doi:10.1371/journal.pone.0078483.
    • (2013) PLoS One , vol.8 , Issue.10
    • Diaz-de-Durana, Y.1    Lau, J.2    Knee, D.3    Filippi, C.4    Londei, M.5    McNamara, P.6
  • 19
    • 33644988431 scopus 로고    scopus 로고
    • Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
    • Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24(7):1169-77. doi:10.1200/JCO.2005.03.6830.
    • (2006) J Clin Oncol , vol.24 , Issue.7 , pp. 1169-1177
    • Cesana, G.C.1    DeRaffele, G.2    Cohen, S.3    Moroziewicz, D.4    Mitcham, J.5    Stoutenburg, J.6
  • 20
    • 76149114584 scopus 로고    scopus 로고
    • CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues
    • Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, Constantinescu A, et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med. 2010;207(1):223-35. doi:10.1084/jem.20091279.
    • (2010) J Exp Med , vol.207 , Issue.1 , pp. 223-235
    • Budhu, S.1    Loike, J.D.2    Pandolfi, A.3    Han, S.4    Catalano, G.5    Constantinescu, A.6
  • 21
    • 65349119978 scopus 로고    scopus 로고
    • CD28 and CTLA-4 coreceptor expression and signal transduction
    • Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229(1):12-26. doi:10.1111/j.1600-065X.2009.00770.x.
    • (2009) Immunol Rev , vol.229 , Issue.1 , pp. 12-26
    • Rudd, C.E.1    Taylor, A.2    Schneider, H.3
  • 22
    • 0028179886 scopus 로고
    • Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells
    • Larsen CP, Ritchie SC, Hendrix R, Linsley PS, Hathcock KS, Hodes RJ, et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol. 1994;152(11):5208-19.
    • (1994) J Immunol , vol.152 , Issue.11 , pp. 5208-5219
    • Larsen, C.P.1    Ritchie, S.C.2    Hendrix, R.3    Linsley, P.S.4    Hathcock, K.S.5    Hodes, R.J.6
  • 23
    • 0027087331 scopus 로고
    • Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy
    • Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71(7):1065-8.
    • (1992) Cell , vol.71 , Issue.7 , pp. 1065-1068
    • Schwartz, R.H.1
  • 25
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. doi:10.1056/NEJMoa1003466.
    • (2010) N Engl J Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3    Weber, R.W.4    Sosman, J.A.5    Haanen, J.B.6
  • 26
    • 84926648478 scopus 로고    scopus 로고
    • Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
    • McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40(9):1056-64. doi:10.1016/j.ctrv.2014.06.012.
    • (2014) Cancer Treat Rev , vol.40 , Issue.9 , pp. 1056-1064
    • McDermott, D.1    Lebbe, C.2    Hodi, F.S.3    Maio, M.4    Weber, J.S.5    Wolchok, J.D.6
  • 28
    • 0030853610 scopus 로고    scopus 로고
    • Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages
    • Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 1997;57(18):4036-41.
    • (1997) Cancer Res , vol.57 , Issue.18 , pp. 4036-4041
    • Yang, Y.F.1    Zou, J.P.2    Mu, J.3    Wijesuriya, R.4    Ono, S.5    Walunas, T.6
  • 29
    • 0033213599 scopus 로고    scopus 로고
    • CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism
    • Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity. 1999;11(4):483-93.
    • (1999) Immunity , vol.11 , Issue.4 , pp. 483-493
    • Shrikant, P.1    Khoruts, A.2    Mescher, M.F.3
  • 30
    • 0032544067 scopus 로고    scopus 로고
    • CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
    • Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A. 1998;95(17):10067-71.
    • (1998) Proc Natl Acad Sci U S A , vol.95 , Issue.17 , pp. 10067-10071
    • Hurwitz, A.A.1    Yu, T.F.2    Leach, D.R.3    Allison, J.P.4
  • 31
    • 33745851479 scopus 로고    scopus 로고
    • CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    • Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116(7):1935-45. doi:10.1172/JCI27745.
    • (2006) J Clin Invest , vol.116 , Issue.7 , pp. 1935-1945
    • Quezada, S.A.1    Peggs, K.S.2    Curran, M.A.3    Allison, J.P.4
  • 33
    • 84858800620 scopus 로고    scopus 로고
    • The immune contexture in human tumours: impact on clinical outcome
    • Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306. doi:10.1038/nrc3245.
    • (2012) Nat Rev Cancer , vol.12 , Issue.4 , pp. 298-306
    • Fridman, W.H.1    Pages, F.2    Sautes-Fridman, C.3    Galon, J.4
  • 34
    • 84920956732 scopus 로고    scopus 로고
    • PD-1 blockade induces responses by inhibiting adaptive immune resistance
    • Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71. doi:10.1038/nature13954.
    • (2014) Nature , vol.515 , Issue.7528 , pp. 568-571
    • Tumeh, P.C.1    Harview, C.L.2    Yearley, J.H.3    Shintaku, I.P.4    Taylor, E.J.5    Robert, L.6
  • 36
    • 36248976097 scopus 로고    scopus 로고
    • CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells
    • Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12):1353-62. doi:10.1038/ni1536.
    • (2007) Nat Immunol , vol.8 , Issue.12 , pp. 1353-1362
    • Pandiyan, P.1    Zheng, L.2    Ishihara, S.3    Reed, J.4    Lenardo, M.J.5
  • 37
    • 0041349288 scopus 로고    scopus 로고
    • Cytokine requirements for the growth and development of mouse NK cells in vitro
    • Toomey JA, Gays F, Foster D, Brooks CG. Cytokine requirements for the growth and development of mouse NK cells in vitro. J Leukoc Biol. 2003;74(2):233-42.
    • (2003) J Leukoc Biol , vol.74 , Issue.2 , pp. 233-242
    • Toomey, J.A.1    Gays, F.2    Foster, D.3    Brooks, C.G.4
  • 38
    • 31144449386 scopus 로고    scopus 로고
    • CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity
    • Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006;176(3):1517-24.
    • (2006) J Immunol , vol.176 , Issue.3 , pp. 1517-1524
    • Hayakawa, Y.1    Smyth, M.J.2
  • 39
    • 1542405768 scopus 로고    scopus 로고
    • NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation
    • Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer J Int du Cancer. 2004;109(4):499-506. doi:10.1002/ijc.11696.
    • (2004) Int J Cancer J Int du Cancer , vol.109 , Issue.4 , pp. 499-506
    • Xu, D.1    Gu, P.2    Pan, P.Y.3    Li, Q.4    Sato, A.I.5    Chen, S.H.6
  • 40
    • 80053371978 scopus 로고    scopus 로고
    • IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice
    • Takeda K, Nakayama M, Sakaki M, Hayakawa Y, Imawari M, Ogasawara K, et al. IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukoc Biol. 2011;90(4):777-85. doi:10.1189/jlb.0411208.
    • (2011) J Leukoc Biol , vol.90 , Issue.4 , pp. 777-785
    • Takeda, K.1    Nakayama, M.2    Sakaki, M.3    Hayakawa, Y.4    Imawari, M.5    Ogasawara, K.6
  • 41
    • 0033517152 scopus 로고    scopus 로고
    • Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
    • van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190(3):355-66.
    • (1999) J Exp Med , vol.190 , Issue.3 , pp. 355-366
    • Elsas, A.1    Hurwitz, A.A.2    Allison, J.P.3
  • 42
    • 48249103057 scopus 로고    scopus 로고
    • Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
    • Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113-8. doi:10.1073/pnas.0711106105.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , Issue.29
    • Onishi, Y.1    Fehervari, Z.2    Yamaguchi, T.3    Sakaguchi, S.4
  • 43
    • 84924340539 scopus 로고    scopus 로고
    • Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
    • Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25(3):399-400. doi:10.1038/cr.2015.28.
    • (2015) Cell Res , vol.25 , Issue.3 , pp. 399-400
    • Hannani, D.1    Vetizou, M.2    Enot, D.3    Rusakiewicz, S.4    Chaput, N.5    Klatzmann, D.6
  • 44
    • 27844458057 scopus 로고    scopus 로고
    • Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study
    • Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12):1005-16. doi:10.1245/ASO.2005.03.536.
    • (2005) Ann Surg Oncol , vol.12 , Issue.12 , pp. 1005-1016
    • Maker, A.V.1    Phan, G.Q.2    Attia, P.3    Yang, J.C.4    Sherry, R.M.5    Topalian, S.L.6
  • 45
    • 84859393995 scopus 로고    scopus 로고
    • CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma
    • Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-47. doi:10.1158/1078-0432.CCR-11-1823.
    • (2012) Clin Cancer Res , vol.18 , Issue.7 , pp. 2039-2047
    • Prieto, P.A.1    Yang, J.C.2    Sherry, R.M.3    Hughes, M.S.4    Kammula, U.S.5    White, D.E.6
  • 46
    • 84857416489 scopus 로고    scopus 로고
    • Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells
    • Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, Waldmann H, et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity. 2012;36(2):262-75. doi:10.1016/j.immuni.2011.12.012.
    • (2012) Immunity , vol.36 , Issue.2 , pp. 262-275
    • Miyao, T.1    Floess, S.2    Setoguchi, R.3    Luche, H.4    Fehling, H.J.5    Waldmann, H.6
  • 47
    • 79953169475 scopus 로고    scopus 로고
    • Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-beta blockade during the perioperative period of tumor resection
    • Bellavance EC, Kohlhapp FJ, Zloza A, O'Sullivan JA, McCracken J, Jagoda MC, et al. Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-beta blockade during the perioperative period of tumor resection. J Immunol. 2011;186(6):3309-16. doi:10.4049/jimmunol.1002549.
    • (2011) J Immunol , vol.186 , Issue.6 , pp. 3309-3316
    • Bellavance, E.C.1    Kohlhapp, F.J.2    Zloza, A.3    O'Sullivan, J.A.4    McCracken, J.5    Jagoda, M.C.6
  • 48
    • 84862801958 scopus 로고    scopus 로고
    • NKG2D signaling on CD8(+) T cells represses T-bet and rescues CD4-unhelped CD8(+) T cell memory recall but not effector responses
    • Zloza A, Kohlhapp FJ, Lyons GE, Schenkel JM, Moore TV, Lacek AT, et al. NKG2D signaling on CD8(+) T cells represses T-bet and rescues CD4-unhelped CD8(+) T cell memory recall but not effector responses. Nat Med. 2012;18(3):422-8. doi:10.1038/nm.2683.
    • (2012) Nat Med , vol.18 , Issue.3 , pp. 422-428
    • Zloza, A.1    Kohlhapp, F.J.2    Lyons, G.E.3    Schenkel, J.M.4    Moore, T.V.5    Lacek, A.T.6
  • 49
    • 84891707105 scopus 로고    scopus 로고
    • Intravascular staining for discrimination of vascular and tissue leukocytes
    • Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc. 2014;9(1):209-22. doi:10.1038/nprot.2014.005.
    • (2014) Nat Protoc , vol.9 , Issue.1 , pp. 209-222
    • Anderson, K.G.1    Mayer-Barber, K.2    Sung, H.3    Beura, L.4    James, B.R.5    Taylor, J.J.6
  • 50
    • 84876693895 scopus 로고    scopus 로고
    • Sensing and alarm function of resident memory CD8(+) T cells
    • Schenkel JM, Fraser KA, Vezys V, Masopust D. Sensing and alarm function of resident memory CD8(+) T cells. Nat Immunol. 2013;14(5):509-13. doi:10.1038/ni.2568.
    • (2013) Nat Immunol , vol.14 , Issue.5 , pp. 509-513
    • Schenkel, J.M.1    Fraser, K.A.2    Vezys, V.3    Masopust, D.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.